CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Suvorexant (dual orexin receptor antagonist) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05546515
NCT05546515Phase 2Completed
CompareCT.gov

Safety and Efficacy of Suvorexant for Opioid/Stimulant Co-use Among Individuals in Treatment for Opioid Use Disorder (OUD)

Johns Hopkins University·interventional·Posted Sep 19, 2022·Updated Dec 23, 2025

In Brief

A Phase 2 clinical trial evaluating Suvorexant (dual orexin receptor antagonist) and Placebo for Opioid Use Disorder and Stimulant Use Disorder. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use Disorder, Stimulant Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedSep 19, 2022
Enrollment StartDec 1, 2022
Primary CompletionNov 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.8 years ago

Interventions

Suvorexant (dual orexin receptor antagonist)drug

Participants will be prescribed up to 30 days of SUVO.

Placebodrug

Participants will be prescribed up to 30 days of placebo medication.